[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100145180":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":41,"centralContacts":25,"locations":45,"responsibleParty":58,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":84,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PF-03049423","ACTIVE_COMPARATOR","Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers",[13],"Drug: PF-03049423",{"label":15,"type":16,"description":17,"interventionNames":18},"Drug","PLACEBO_COMPARATOR","Placebo in oral solution, given once daily for 14 days",[19],"Drug: Placebo",[21,26,29,32,35,38],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers",[9],null,{"type":22,"name":9,"description":27,"armGroupLabels":28,"otherNames":25},"PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers",[9],{"type":22,"name":9,"description":30,"armGroupLabels":31,"otherNames":25},"PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers",[9],{"type":22,"name":9,"description":33,"armGroupLabels":34,"otherNames":25},"PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers",[9],{"type":22,"name":9,"description":36,"armGroupLabels":37,"otherNames":25},"PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers",[9],{"type":22,"name":39,"description":17,"armGroupLabels":40,"otherNames":25},"Placebo",[15],[42],{"name":43,"affiliation":5,"role":44},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[46],{"facility":47,"status":25,"city":48,"state":25,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":25},"Pfizer Investigational Site","Brussels","1070","Belgium","BE",{"type":53,"coordinates":54},"Point",[55,56],4.34878,50.85045,{"lat":56,"lon":55},{"type":25,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":59,"oldOrganization":60},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100145180","phase-1-a-study-to-evaluate-the-safety-and-tolerability-of-different-doses-of-pf-03049423-in-healthy-adult-volunteers-and-healthy-older-volunteers-100145180",false,"NCT01161069","A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers","A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Multiple Dose Escalation Study To Evaluate The Safety, Toleration, Pharmacokinetics Of PF-03049423 In Healthy Young Adult Volunteers And Healthy Elderly Volunteers","Inclusion Criteria:\n\n* Healthy persons, male or female.\n* For the healthy young adult cohort, subjects must be 18 to 50 years old, inclusive.\n* For the healthy elderly adult cohort, subjects must be 51 to 99 years old, inclusive.\n* Body Mass Index (BMI) of 18 to 35; and a total body weight \\>50 kg (110 lbs)\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical conditions.\n* Women of non-child bearing potential.\n* Subjects with a known medical history of hearing loss\u002Fdisability or nonarteritic ischemic optic neuropathy.\n* A positive urine drug screen.",true,"ALL","18 Years",{"count":72,"type":73},48,"ACTUAL","INTERVENTIONAL",[76],"PHASE1","The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly volunteers. The study will also evaluate the pharmacokinetics of PF-03049423 after multiple dose administration to healthy young adult volunteers and healthy elderly volunteers. The study will also explore the relationship between blood pressure (supine and standing) and PF-03049423 concentration.",[79],"Healthy",[81,82,83],"phase 1","healthy young adult volunteers","healthy elderly adult volunteers","COMPLETED","2011-08-08",{"date":87,"type":88},"2011-08-09","ESTIMATED",{"date":90,"type":25},"2009-08",{"date":92,"type":73},"2009-12",{"name":5,"class":6},1]